Role of Hematopoietic Growth Factors in the Prevention of Neutropenic Complications for Breast Cancer Patients Treated with Docetaxel, Doxorubicin, and Cyclophosphamide (TAC): Results of a Randomized Double-Blind Phase III Trial

1
Role of Hematopoietic Growth Factors in the
Prevention of Neutropenic Complications for
Breast Cancer Patients Treated with Docetaxel,
Doxorubicin, and Cyclophosphamide (TAC) Results
of a Randomized Double-Blind Phase III
Trial BCIRG 004
John R. Mackey1, Jacques Cantin2, Jose Chang3,
Raymond Guervin4, Ravi Patel5, Katherine
Tkaczuk6, Pavel Vodvarka7, Michael Needle8,
Thomas Peppard8, Jeffery Nieves8, Jean-Marc
Nabholtz9, on behalf of the Breast Cancer
International Research Group 1Cross Cancer
Institute, Edmonton, AB, Canada 2CHUM Campus
Hotel Dieu, Montreal, QC, Canada 3Oshawa general
Hospital/Lakeridge Health Oshawa, Oshawa, ON,
Canada 4CHUM Pavillon Saint-Luc, Montreal, QC,
Canada 5Comprehensive Blood and Cancer Center,
Bakersfield, CA 6Greenebaum Cancer Centre,
Baltimore, MD 7FNsP Ostrava, Ostrava - Poruba,
Czech Republic 8Pharmacia, Skokie, IL 9Univ.
California at Los Angeles, CA.